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Introduction: Accurate diagnosis of idiopathic pulmonary ﬁbrosis (IPF) has important therapeutic and
prognostic implications and would be greatly aided by reliable diagnostic biomarkers as IPF has some-
times overlapping features with other interstitial lung diseases (ILD).
Objectives: To explore the value of serum metalloproteinases (MMP) 1 and 7 levels in the differential
diagnosis of IPF with other ILD.
Methods: MMP-1/7 serum levels were measured using Luminex xMAP technology in 139 patients- 47
IPF, 36 non-IPF Usual Interstitial Pneumonia (UIP), 14 idiopathic Nonspeciﬁc Interstitial Pneumonia
(iNSIP), 29 secondary NSIP (secNSIP), 13 stage IV sarcoidosis- and 20 healthy controls, and compared
using the ManneWhitney U test.
Results: MMP-1 was signiﬁcantly higher in IPF than non-IPF UIP (P ¼ .042) and sarcoidosis (P ¼ .027).
MMP-7 was signiﬁcantly higher in IPF than controls (P < .001), non-IPF UIP (P ¼ .003), secNSIP (P < .001),
and sarcoidosis (P < .001). The Area Under the Curve for IPF versus other ILD was 0.63 (95%CI, 0.53e0.73)
for MMP-1, 0.73 (95%CI, 0.65e0.81) for MMP-7, and 0.74 (95%CI, 0.66e0.82) for MMP-1/MMP-7 com-
bined. Sensitivity and speciﬁcity for MMP-7 cutoff ¼ 3.91 ng/mL was 72.3% and 66.3%, respectively,
Positive Predictive Values ¼ 52.3% and Negative Predictive Values ¼ 82.4%.
Conclusions: MMP-1 and particularly MMP-7 serum levels were signiﬁcantly higher in IPF than in non-
IPF UIP, the main entity in differential diagnosis. The value of these biomarkers as additional tools in a
multidisciplinary approach to IPF diagnosis needs to be considered and further explored.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
Idiopathic pulmonary ﬁbrosis (IPF) is a chronic ﬁbrosing lung
disease characterized by progressive functional deterioration and a
median survival of 2e3 years from the time of diagnosis [1e3]. It is
associated with a radiological and histological pattern of usual
interstitial pneumonia (UIP) and is the most common form of
idiopathic interstitial pneumonia [1,4]. Although its pathogenesis is
largely unknown, IPF is assumed to be caused by aberrant tissue
repair and remodeling following recurrent alveolar epithelial injuryCentro Hospitalar S~ao Jo~ao,
319, Portugal.
. Morais).(the nature of which is currently unknown), leading to a persistent
and progressive disordered ﬁbroproliferation [2,5,6]. Since the UIP
pattern is not pathognomonic, IPF is always a diagnosis of exclu-
sion, with ruling out of interstitial lung diseases related to con-
nective tissue lung disorders (CTD-ILDs), hypersensitivity
pneumonitis (HP), and drug lung toxicity [1,7,8]. Moreover, in cases
without typical radiological UIP features (e.g., possible UIP pattern),
it can be very difﬁcult to distinguish between IPF and conditions
such as idiopathic or secondary ﬁbrotic nonspeciﬁc interstitial
pneumonia (NSIP) [1,7]. An accurate diagnosis of IPF is of key
importance considering the therapeutic and prognostic implica-
tions, and surgical lung biopsy is required in cases with an incon-
clusive diagnosis [1,7]. Biopsy, however, is an invasive procedure,
with attendant risks (e.g, acute exacerbation in IPF), and
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serious comorbidities [1,9,10].
Both clinicians and patients, therefore, would beneﬁt greatly
from reliable IPF diagnostic biomarkers. While several recent
studies have identiﬁed and suggested a potential diagnostic or
prognostic role for certain peripheral blood biomarkers (e.g., Krebs
von den Lungen 6 antigen [KL-6], glycoprotein, surfactant proteins
A and D, chemokine CCL-18, vascular endothelial growth factor, and
glycoprotein YKL-40), none of these candidate markers has been
validated or clinically accepted [11,12].
The matrix metalloproteinases (MMPs) belong to the zinc-
dependent endoproteases that participate in extracellular matrix
remodeling, wound healing, and angiogenesis and have been
implicated in the pathogenesis of IPF [13,14]. Microarray studies
have shown several members of the MMP family to be highly
upregulated in IPF lungs, and elevated protein expression (MMP-
1,2,3,7,8,9) has been found in the bronchoalveolar lavage ﬂuid
(BALF) and blood of IPF patients [13,15e20]. However, based on the
available data, MMP-1 and MMP-7 are the most signiﬁcantly
overexpressed proteins in the lungs of patients with IPF compared
with healthy controls [14]. Moreover, using a panel of 49 plasma
proteins in a group of IPF patients, Rosas et al. [19] found increased
concentrations of both MMP-1 and MMP-7, suggesting not only a
determinant role in IPF pathogenesis but also potential utility as
biomarkers in the differential diagnosis of this disease.
Although signiﬁcant differences have been described for MMP-1
and MMP-7 expression in IPF compared with other ILDs, namely
sarcoidosis and HP (mostly subacute forms), a direct comparison
has never been made with conditions that pose the main challenge
in the differential diagnosis of IPF [19]. The aim of our research was
to compare serum MMP-1 and MMP-7 levels in IPF, non-IPF UIP,
and ﬁbrotic NSIP.
2. Material and methods
2.1. Patients and controls
We included 139 patients followed at the Interstitial Lung Dis-
eases outpatient clinic at Centro Hospitalar S~ao Jo~ao, a tertiary
referral center serving patients mostly from the north of Portugal.
The patients were classiﬁed into 3 groups: IPF (n¼ 47), non-IPF UIP
(n¼ 36), and ﬁbrotic NSIP (n¼ 43). The non-IPF UIP group included
21 patients with HP (12 with bird fancier's disease, 6 with sube-
rosis, and 3 with unknown etiology), 13 with CTD (7 with systemic
sclerosis, 5 with rheumatoid arthritis, and 1 with undifferentiated
CTD), and 2 with amiodarone lung toxicity. In the ﬁbrotic NSIP
group, there were 14 patients with idiopathic NSIP and 29 with
NSIP secondary to an underling CTD (13 with systemic sclerosis, 8
with rheumatoid arthritis, 3 with Sj€ogren syndrome, 2 with mixed
CTD, 2 with dermatopolymyositis, and 1 with systemic lupus ery-
thematosus). Additionally, we included 13 patients with stage IV
sarcoidosis and a control group of 20 healthy individuals (mean
[SD] age of 70.3 [6.4] years, 9 females [45%]) with no history of lung
disease or respiratory symptoms, or evidence of other diseases by
chest radiography. Written informed consent was obtained from all
individuals, and the study was approved by the hospital's ethics
committee.
Patients with IPF were diagnosed according to the 2011 Euro-
pean Respiratory Society (ERS)/American Thoracic Society (ATS)/
Japanese Respiratory Society/Latin American Thoracic Society
Guidelines [1]. CTDs were diagnosed following The European
League Against Rheumatism (EULAR) Recommendations [21]. All
patients with NSIP underwent surgical lung biopsy, with appli-
cation of the 2002 ATS/ERS International Multidisciplinary
Consensus Classiﬁcation of the Idiopathic Interstitial Pneumonias[22]. CTD-ILD diagnosis was based on high-resolution computed
tomography (HRCT) ﬁndings, BALF features, and a previous CTD
diagnosis [23]. HP was diagnosed using the criteria proposed by
Lacasse et al. [24] Eleven (84.6%) of the 13 patients with sarcoid-
osis had histological conﬁrmation in a compatible clinical and
radiological context and the other 2 fulﬁlled criteria established in
the consensus statement on sarcoidosis by the ERS/ATS/World
Association of Sarcoidosis and Other Granulomatous Diseases
(WASOG) [25], namely compatible clinical and radiographic fea-
tures, a BALF CD4/CD8 lymphocyte ratio of >4.0, and a 2-year
observation period to exclude other medical conditions. All
radiological exams were evaluated by 2 radiologists and patho-
logic samples were analyzed by 2 pathologists, all trained in ILD
evaluation. All the diagnoses were discussed and established by a
multidisciplinary group including lung physicians, radiologists,
and pathologists.
2.2. Blood samples
Blood samples were collected by venipuncture using Terumo
Venosafe Serum-Gel tubes. Serum was separated within 30 min
of blood collection following centrifugation for 10 min at 400
g. The serum samples were stored in aliquots at 80 C until
use.
MMP-1 and MMP-7 were measured using a human multiplex
analysis assay (R&D Systems, Inc.) according to the manufacturer's
protocol. Brieﬂy, the assay is based on the Fluorokine MAP multi-
plex technology (Luminex Corporation), which combines the
principle of a sandwich immunoassay with ﬂuorescent-bead-based
technology. Appropriate standards and serum samples were
diluted (10-fold) in calibrator diluents and added to pre-wet ﬁlter-
bottomed microplates. Fluorescent beads containing MMP-1 and
MMP-7 antibodies were added and incubated on a plate shaker for
2 h at room temperature. After washing, biotinylated detection
antibodies were added to each well, incubated for 1 h at room
temperature, washed, and incubated for a further 30 min with a
streptavidin-phycoerythrin conjugate. After washing, the beads
were resuspended in wash buffer and analyzed on a Luminex 200
instrument. Mean ﬂuorescent intensity data were analyzed using
the Luminex 100 Integrated System version 2.3. The generation of a
standard curve using standard MMP concentrations allowed the
measurement of each metalloproteinase individually. The mini-
mum detectable dose for MMP-1 and MMP-7 was 4.4 and 16.9 pg/
mL, respectively.
2.3. Statistical analysis
Analysis of variance or KruskaleWallis tests (for nonnormally
distributed variables) were used to compare continuous variables
and the c2 test was used to compare proportions of demographic
characteristics and MMP distributions according to diagnosis. The
ManneWhitney U test was used for pairwise comparison of the
distribution of MMP-1 and MMP-7 serum levels in IPF patients
versus controls and patients with other diagnoses. To calculate the
associations of MMP-1 and MMP-7 independently with each dis-
order we computed logistic regression models adjusting for age,
sex, and smoking history (never vs former or current smokers). A P
value of less than 0.05 was considered signiﬁcant and all P values
were 2-sided.
Receiver operating characteristic (ROC) analysis was used to
determine the area under the curve (AUC) for MMP-1, MMP-7, and
MMP-1/MMP-7 combined with regard to IPF diagnosis versus any
other diagnosis (excluding controls). Sensitivity, speciﬁcity, and
positive and negative predictive values (PPV and NPV, respectively)
were calculated for the cutoffs of MMP-1 and MMP-7, and the
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establish the best cutoff for IPF diagnosis.Fig. 1. White circles represent mild outliers and black circles represent extreme out-
liers. MMP-1 levels in patients and controls. Levels were signiﬁcantly higher in IPF than
in non-IPF UIP (P ¼ .042) and sarcoidosis (P ¼ .027). MMP indicates matrix metal-
loproteinase; IPF, idiopathic pulmonary ﬁbrosis; non-IPF UIP, non-IPF usual interstitial
pneumonia; iNSIP, idiopathic nonspeciﬁc interstitial pneumonia; secNSIP, NSIP sec-
ondary to a connective tissue lung disorder; UIP, usual interstitial pneumonia.3. Results
Patient demographics and characteristics according to diagnosis
are presented in Table 1, together with statistically signiﬁcant
between-group differences based on the expected clinical charac-
teristics of each group [21]. Healthy controls and IPF patients had a
similar mean (SD) age (70.3 [6.4] vs 70.6 [9.5] years, P ¼ .865) and
sex distribution (9 females [45.0%] vs 17 [36.2%], P ¼ .686) and
similar proportions of smokers (11 [55.0%] vs 28 [62.2%], P ¼ .583).
A signiﬁcant difference was found for the mean serum con-
centration of MMP-7 but not MMP-1 across the groups (Table 1).
MMP-1 concentration, however, was signiﬁcantly higher in IPF
than in non-IPF UIP (P ¼ .042) and sarcoidosis (P ¼ .027) (Fig. 1).
MMP-7 levels were signiﬁcantly higher in IPF patients than in
controls (P < .001) and patients with non-IPF UIP (P ¼ .003), sec-
ondary NSIP (P < .001), and sarcoidosis (P < .001) (Fig. 2).
In the multivariate logistic regression models for each diagnosis
(Table 2), MMP-7 was independently associated with IPF
(OR ¼ 1.34; 95% CI, 1.17e1.54) and an inverse associationwas found
for sarcoidosis (OR ¼ 0.66; 95% CI, 0.45e0.96), ie, lower levels of
MMP-7 were associated with the diagnosis of sarcoidosis. The as-
sociation between MMP-7 and IPF remained signiﬁcant after
adjusting for sex, age and smoking history. No further signiﬁcant
associations were observed.
The AUC of the ROC curve for the diagnosis of IPF versus all other
diagnoses was 0.63 (95% CI, 0.53e0.73) for MMP-1, 0.73 (95% CI,
0.65e0.81) for MMP-7, and 0.74 (0.66e0.82) for MMP-1 and MMP-
7 combined (Fig. 3)
The best combination of sensitivity and speciﬁcity for MMP-7
was obtained for the cutoff of 3.91 ng/mL (72.3% and 66.3%,
respectively), with a PPV of 52.3% and a NPV of 82.4%
(Supplementary Table). As lower cutoffs were selected, higher NPVs
were achieved, demonstrating better performance for each MMP in
ruling out IPF.
4. Discussion
We evaluated the potential value of MMP-1 and MMP-7 as
diagnostic biomarkers for IPF by comparing serum concentrations
in IPF patients and patients with other ILDs that pose a challenge in
the differential diagnosis (non-IPF UIP and secondary and idio-
pathic ﬁbrotic NSIP). Both MMP-1 and MMP-7 serum levels were
signiﬁcantly higher in IPF patients than in patients with non-IPF
UIP and sarcoidosis. Moreover, MMP-7 levels were signiﬁcantly
higher in IPF patients than in patients with secondary NSIP and
healthy controls (with a similar age, sex distribution and smoking
habits). MMP-7 performed better than MMP-1 for the diagnosis ofTable 1
Patients characteristics according to diagnosis.
UIP NSIP
IPF (n ¼ 47) Non-IPF (n ¼ 36) iNSIP (n ¼ 14)
Age, mean (SD), y 70.6 (9.5) 65.4 (11.5) 62.4 (12.1)
Female, No. % 17 (36.2) 24 (66.7) 10 (71.4)
Ex/current smokers, No. (%) 28 (62.2) 5 (13.9) 4 (28.6)
Never smokers, No. (%) 17 (37.8) 31 (86.1) 10 (71.4)
MMP-1, mean (SD), ng/mL 5.79 (5.20) 4.02 (3.85) 4.43 (3.59)
MMP-7, mean (SD), ng/mL 5.79 (3.07) 4.07 (2.73) 4.32 (2.90)
Abbreviations: iNSIP, idiopathic NSIP; MMP, matrix metalloproteinase; NSIP, nonspeciﬁc i
UIP, usual interstitial pneumonia.
a Comparing all groups.IPF, as measured by the AUC, with a cutoff of 3.91 ng/mL providing
maximum sensitivity and speciﬁcity and an NPV of 82.4%.
IPF is the most severe of the idiopathic interstitial pneumonias,
with a distinctive therapeutic approach and a poor prognosis.
Consequently, a conﬁdent diagnosis and a clear distinction from
other ﬁbrotic ILDs have important clinical implications in terms of
patient outcome and treatment options. Approximately one-third
of IPF patients require surgical lung biopsy, which has inherent
risks and is not always feasible [1]. Clinicians, therefore, need bio-
markers not only to predict outcome and survival, but also to
establish a reliable diagnosis.
An ideal biomarker should be easily accessible, amenable to
reliable measurement, and suitable for use in longitudinal assess-
ment [11,12]. Increasing evidence is being amassed on the potential
value of MMPs in IPF [14,16]. Rosas et al. [19] analyzed 49 potential
IPF serummarkers and found 5MMPs (includingMMP-1 andMMP-
7) among the 12 proteins that were differentially expressed.
Moreover, MMP-1 and MMP-7 were signiﬁcantly overexpressed in
IPF patients compared with patients with sarcoidosis or chronic
obstructive pulmonary disease (COPD), and enhanced MMP-7
expression was seen in both lung tissue and BALF.
In addition to experimental data [26,27], several investigations
with lung tissue, BALF, and peripheral blood support a possible role
of MMPs in the pathogenesis of IPF, namely through theirSarcoidosis (n ¼ 13) Controls (n ¼ 20) P Valuea
secNSIP (n ¼ 29)
61.1 (9.5) 53.9 (12.6) 70.3 (6.4) <.001
26 (89.7) 7 (53.8) 9 (45.0) <.001
8 (27.6) 4 (30.8) 11 (55.0) <.001
21 (72.4) 9 (69.2) 9 (45.0)
4.93 (5.25) 3.22 (2.96) 4.89 (3.11) .200
3.76 (2.62) 2.39 (1.68) 1.52 (0.77) <.001
nterstitial pneumonia; secNSIP, NSIP secondary to a connective tissue lung disorder;
Fig. 2. White circles represent mild outliers and black circles represent extreme out-
liers. MMP-7 levels in patients and controls. Levels were signiﬁcantly higher in IPF
patients than in controls (P < .001), patients with non-IPF UIP (P ¼ .003), secondary
NSIP (P < .001), and sarcoidosis (P < .001). MMP indicates matrix metalloproteinase;
IPF, idiopathic pulmonary ﬁbrosis; non-IPF UIP, non-IPF usual interstitial pneumonia;
iNSIP, idiopathic nonspeciﬁc interstitial pneumonia; secNSIP, NSIP secondary to a
connective tissue lung disorder; UIP, usual interstitial pneumonia.
Fig. 3. Receiver operator characteristic (ROC) curves for MMP-1 and MMP-7
comparing idiopathic pulmonary ﬁbrosis and all other diagnoses. *The combined
variable (MMP-1 & MMP-7) is the predicted probability extracted from a logistic
regression model ﬁtted for IPF diagnosis vs other, using MMP-1 and MMP-7 as
covariates.
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involved not only in the degradation of matrix components, but
also in the modulation of a variety of bioactive mediators, such as
cytokines and chemokines [13,14]. MMPs are regulated at tran-
scriptional and posttranscriptional levels by inhibitors and in-
ducers, creating a delicate balance in extracellular matrix
remodeling [13,14]. Their expression, usually modest under physi-
ological conditions, increases in repair processes such as wound
healing, and uncontrolled MMP activity results in tissue damage
and functional changes [14].
MMP-7, the smallest member of the MMP family, has a proﬁ-
brotic proﬁle with diverse biological functions, ranging from innate
immunity to inﬂammation, apoptosis, and ﬁbroproliferation
[27,28]. It is also able to process numerous bioactive substrates and
activate proteases, including itself. The release of preformed TGF-b
from extracellular matrix is the main regulation process related to
TGF bioactivity, one of the presumptive mediators in IPF patho-
genesis. In an animal model, MMP-7 knockout mice treated with
bleomycin did not develop lung ﬁbrosis [29]. Additionally, MMP-7
has been found on the surface of epithelial cells and alveolar
macrophages in IPF lung tissue, but not in healthy lung tissue
[30,31]. Interestingly, enhanced levels of serum MMP-7 were alsoTable 2
Odds ratios (95% CI) for the association of MMP-1 and MMP-7 with each diagnosis.
IPF Non-IPF UIP
MMP-1a 1.07 (0.99e1.15) 0.94 (0.85e1.04)
MMP-1 adjustedb 1.04 (0.96e1.13) 0.95 (0.85e1.05)
MMP-1 adjustedc 1.05 (0.97e1.14) 0.94 (0.85e1.04)
MMP-7 1.34 (1.17e1.54)a 1.00 (0.88e1.13)
MMP-7 adjustedb 1.39 (1.18e1.63)a 1.00 (0.87e1.14)
MMP-7 adjustedc 1.40 (1.18e1.66)a 1.00 (0.87e1.14)
Abbreviations: IPF, idiopathic pulmonary ﬁbrosis; MMP, matrix metalloproteinase; NSIP
lung disorder; UIP, usual interstitial pneumonia.
a P < .05.
b Adjusted for age and sex.
c Adjusted for age, sex, and smoking status (smoking status variable was dichotomizefound in patients with asymptomatic IPF (although at lower levels
than in symptomatic patients), pointing to its possible value as a
marker for both early disease and progression [28]. In fact, BALF and
serum MMP-7 levels showed not only a negative correlation with
forced vital capacity and diffusing capacity but also an independent
association with IPF mortality [3,19,20,31].
The potential role of MMP-7 as a differential biomarker in IPF is
still unclear, particularly when clinically similar ILDs are involved.
In fact, Rosas et al. compared IPF with sarcoidosis and COPD, which
clearly have distinct clinical and radiological features. Although the
study included patients with HP mostly with subacute presenta-
tion, the major confounding diagnosis is chronic advanced HP
associated with ﬁbrosis, particularly with UIP pattern. Our study,
which showed signiﬁcantly higher serum MMP-7 levels in IPF
compared with non-IPF UIP, is the ﬁrst, to our knowledge, to
investigate the value of this marker in distinguishing IPF from other
ILDs with the UIP pattern.
Vuorinen et al. [18] described a higher level of MMP-7 in the
BALF of IPF patients compared with controls, with no signiﬁcant
differences for idiopathic NSIP or sarcoidosis. In our series, while
we did not ﬁnd signiﬁcant differences for serum MMP- 7 levels
between IPF and idiopathic NSIP, we did observe signiﬁcantlyNSIP secNSIP Sarcoidosis
0.98 (0.85e1.12) 1.01 (0.92e1.10) 0.86 (0.68e1.08)
1.00 (0.88e1.14) 1.06 (0.97e1.15) 0.88 (0.68e1.13)
1.00 (0.88e1.14) 1.06 (0.96e1.15) 0.88 (0.69e1.12)
1.03 (0.86e1.23) 0.95 (0.82e1.10) 0.66 (0.45e0.96)a
1.06 (0.88e1.28) 1.00 (0.85e1.17) 0.72 (0.48e1.08)
1.06 (0.88e1.28) 1.00 (0.85e1.17) 0.73 (0.49e1.09)
, nonspeciﬁc interstitial pneumonia; secNSIP, NSIP secondary to a connective tissue
d: former or current smokers vs never smokers).
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similar gene expression patterns have been found in IPF and some
NSIP cases, but there are clear differences when other ILDs that can
nevertheless express an UIP or NSIP pattern are considered [15].
Moreover, all the patients with idiopathic NSIP included had
thoracic HRCT features alike UIP instead of HP or organizing
pneumonia like features, the two other possible patterns described
in this entity. Vuorinen et al. showed lung MMP-7 immunoreac-
tivity in some ﬁbroblastic foci, vascular smooth muscle cells, and
areas of hyperplastic epithelium in IPF samples; in NSIP samples
immunoreactivity was observed in areas of inﬂammation beneath
the alveolar epithelium. These ﬁndings suggest that MMP-7 may
have relevant but different roles in the pathophysiologic processes
involved in different ILDs, but the differences might not be quan-
titatively detectable. Moreover, although idiopathic NSIP is associ-
ated with a better prognosis, it is sometimes difﬁcult to clearly
distinguish from IPF on HRCT. Furthermore, the 2 entities have a
similar BALF proﬁle and some patients with IPF show NSIP areas in
their surgical biopsy. The above observations suggest that IPF and
NSIP may possibly be connected.
Our results concerning sarcoidosis contrast with those of
Vuorinen et al. [18] since we found signiﬁcant lowMMP-7 levels in
comparison with IPF. They are in agreement with Rosas et al. [19]
and Zhou et al. [32] ﬁndings, but our study is the ﬁrst to include
only sarcoidosis patients with lung ﬁbrosis. Themajority of patients
studied by Vuorinen et al. did not have signiﬁcant lung disease,
while those studied by Zhou et al. had stage II sarcoidosis. In
another study, Huh et al. [33] found no signiﬁcant differences in
BALF MMP-7 levels between patients with IPF and cryptogenic
organizing pneumonia (COP) although it included few patients and
COP is rarely confused with UIP.
Like MMP-7, MMP-1 has multiple biological functions that may
be involved in the pathogenesis of IPF, such as cytokine processing,
cell migration and growth regulation. MMP-1 expression in IPF
seems to be primarily in the alveolar epithelium and is not
observed in ﬁbroblastic foci or in the interstitial compartment,
where interstitial collagens are secreted and accumulated, respec-
tively [13,28]. It has also been suggested that MMP-1 might
contribute to the formation of cystic spaces, resulting in the char-
acteristic honeycombing pattern seen in IPF [14]. MMP-1 has been
shown to be upregulated in the lung tissue of IPF compared to HP
patients and healthy controls [15,34]. To our knowledge, ours is the
ﬁrst report to show signiﬁcantly higher serum MMP-1 levels in IPF
compared with non-IPF UIP. The signiﬁcantly lower MMP-1 levels
detected in sarcoidosis are consistent with the ﬁndings of Rosas
et al. [19].
The relatively small sample size for some of the clinical entities
considered in our analysis, particularly idiopathic NSIP, is the main
limitation of this study. The cutoff values used were based on the
distribution of MMPs in this particular sample of patients and thus
could vary in other groups. Replications of our ﬁndings are there-
fore needed. While it is largely believed that a combination of
biomarkers has a greater likelihood of becoming a reliable diag-
nostic tool for IPF than any single biomarker, combinations can be
difﬁcult to implement for methodological and economic reasons.
Our data show that MMP-7 is clearly the best differentiator but,
unlike previous studies, we found that its speciﬁcity improved only
marginally when MMP-1 was added.
In conclusion, our results provide additional support for the
potential value of serum MMP-1 and MMP-7 concentrations as
diagnostic biomarkers in IPF. Since non-IPF UIP poses the main
challenge in the differential diagnosis of IPF, the implications of
signiﬁcantly higher levels of MMP-1 and, in particular, MMP-7 in
IPF patients need to be carefully considered as potential tools in the
multidisciplinary diagnostic approach to IPF.Authors contribution
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